JD Health International Inc. (JD Health) reported through a Next Day Disclosure Return that it repurchased 500,000 ordinary shares on 23 June 2026. The on-market transactions were executed at prices between HK$33.04 and HK$34.16 per share, for a total consideration of HK$16.65 million, implying an average purchase price of HK$33.31.

Key share data (as at 23 June 2026): • Issued shares outstanding (excluding treasury shares) remained unchanged at 3.21 billion. • No new shares were issued; all changes relate to buy-backs.

Share buy-back programme: • The 23 June repurchase lifts the total shares bought back but not yet cancelled since the current programme began on 15 May 2026 to 19.44 million, equivalent to 0.61% of JD Health’s existing share capital. • Purchase prices during the programme have ranged from HK$33.04 to HK$45.17 per share. • All 19.44 million repurchased shares are intended for cancellation.

Mandate utilisation: • The buy-backs form part of the authority granted on 20 June 2025 permitting repurchases of up to 320.01 million shares. • To date, 19.44 million shares have been acquired under this mandate, utilising roughly 6.08% of the authorised limit.

Capital management outlook: • Following the latest transaction, JD Health is subject to a 30-day moratorium—until 23 July 2026—on issuing new shares or disposing of any treasury shares, in accordance with Hong Kong Listing Rule 10.06(3)(a).

The company’s issued share count and share capital structure otherwise remain unchanged since the previous disclosure dated 22 June 2026.